Cantor Fitzgerald Issues Positive Outlook for CAPR Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR) – Research analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for Capricor Therapeutics in a report issued on Tuesday, April 1st. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will earn ($1.11) per share for the year, up from their prior estimate of ($1.39). Cantor Fitzgerald currently has a “Overweight” rating and a $30.00 target price on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. The company had revenue of $11.13 million during the quarter, compared to the consensus estimate of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%.

Separately, HC Wainwright reissued a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday, March 17th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Stock Up 2.7 %

Capricor Therapeutics stock opened at $9.74 on Thursday. The firm’s fifty day moving average is $13.72 and its 200 day moving average is $15.03. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40. The company has a market capitalization of $444.88 million, a PE ratio of -9.19 and a beta of 4.09.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds have recently made changes to their positions in CAPR. Charles Schwab Investment Management Inc. grew its position in Capricor Therapeutics by 51.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock worth $1,536,000 after buying an additional 37,868 shares in the last quarter. Magnus Financial Group LLC purchased a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $276,000. JPMorgan Chase & Co. lifted its position in Capricor Therapeutics by 419.5% during the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company’s stock valued at $855,000 after purchasing an additional 45,381 shares during the last quarter. State Street Corp grew its stake in Capricor Therapeutics by 27.8% in the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after buying an additional 111,291 shares in the last quarter. Finally, Swiss National Bank purchased a new position in Capricor Therapeutics in the 4th quarter worth approximately $930,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.